Bulletin
Investor Alert

Coronavirus Update Archives | Email alerts

April 17, 2021, 9:34 a.m. EDT

More than 3 million people have died of COVID-19 and more than 140 million have been infected

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    AstraZeneca PLC ADR (AZN)
  • X
    AstraZeneca PLC (AZN)

or Cancel Already have a watchlist? Log In

Ciara Linnane

The global death toll from the coronavirus-borne illness COVID-19 climbed above 3 million on Saturday and the case tally rose above 140 million, a day after the World Health Organization warned that cases have almost doubled in the last two months, and are now approaching the highest rate seen since the start of the pandemic.

“Some countries that had previously avoided widespread covid-19 transmission are now seeing steep increases in infections,” WHO Director-General Tedros Adhanom Ghebreyesus told reporters at a briefing.

Case numbers are climbing in nearly all regions, including the Americas, with India, Brazil, Poland and Turkey becoming hot spots. Experts say part of the surge is due to new variants that are more infectious than the original virus. But the gradual easing of restrictions in some places and overall pandemic fatigue are also contributing to the trend.

In the U.S., the Centers for Disease Control and Prevention advisory committee said it will reconvene on April 23 to discuss the blood-clotting issue that has led regulators to pause the rollout of Johnson & Johnson’s /zigman2/quotes/201724570/composite JNJ +0.45% vaccine.

The committee gathered on Wednesday to comb through the data and attempt to understand why six women who were given the vaccine developed a very rare blood clotting disorder, and voted to extend the “pause” and reconvene at a later date. 

Read: Johnson & Johnson pause ‘will not have a significant impact on our vaccination plan,’ White House says

Much of the discussion focused on whether committee members needed additional clinical information before making a formal recommendation or whether waiting to make a choice would further harm Americans at risk for contracting COVID-19.

The J&J vaccine was granted an emergency use authorization by the U.S. Food and Drug Administration amid much ballyhoo, as it is viewed as an easier and more equitable tool in the nation’s mass vaccination program because it only requires one shot and can be administered in people’s homes or in mobile units. The other vaccines require two doses set weeks apart and come with stringent storage requirements.

The J&J vaccine also offered a beacon of hope for the rest of the world, and especially for developing countries that are trailing badly in the race to get people vaccinated. The United Nations and WHO have consistently called on wealthier countries not to hog vaccines and have argued that doing so allows new variants to emerge, some of which may prove resistant to the existing vaccines.

The blood clotting issue, which has also been linked to the vaccine developed by AstraZeneca PLC /zigman2/quotes/200304487/composite AZN +0.62% /zigman2/quotes/203048482/delayed UK:AZN +0.72% and Oxford University, has undermined confidence in vaccines in some countries where citizens are already skeptical of them thanks to a legacy of colonialism and dubious medical practices by Western companies, the New York Times reported.

See also: Getting COVID creates far higher risk of rare blood clots than vaccines, Oxford study finds

In Malawi, people are asking doctors how to flush the AstraZeneca vaccine from their bodies, the paper reported Friday. In South Africa, health officials have stopped giving the  J&J shot, two months after dropping the AstraZeneca vaccine. And in the Democratic Republic of Congo, 1.7 million AstraZeneca doses have gone unused, according to the Times.

Dr. Sara Oliver of the C.D.C. told the advisory panel that prolonging the pause in using the Johnson & Johnson vaccine “could have global implications.”

The U.S. vaccine program, meanwhile, continues to show good progress. The Centers for Disease Control and Prevention’s vaccine tracker is showing that as of 6 a.m. Eastern time Friday, 258.5 million doses had been delivered to states, 202.3 million doses had been administered, and 127.7 million people had received at least one shot, equal to 38.5% of the population.

Read now: Here’s how the ‘pause’ on J&J’s COVID-19 shot may or may not affect the company’s earnings

A full 80.6 million people, or 24.3% of the population, are fully vaccinated, meaning they have received two shots of the two-dose vaccines developed by Pfizer Inc. /zigman2/quotes/202877789/composite PFE +1.00% and German partner BioNTech SE /zigman2/quotes/214419716/composite BNTX +9.35% and Moderna Inc. /zigman2/quotes/205619834/composite MRNA +1.65% , or one shot of the Johnson & Johnson /zigman2/quotes/201724570/composite JNJ +0.45% one-shot vaccine. The AstraZeneca vaccine has not been authorized for use in the U.S.

Among Americans aged 65 years and older, 35.3 million are fully vaccinated, equal to 64.6% of that group. Almost 44 million people in that age bracket have received a first jab, covering 80.4% of that population.

See also: Why comparing blood clot risks from COVID-19 vaccines and birth control pills doesn’t work

Among Americans aged 65 years and older, 35.3 million are fully vaccinated, equal to 64.6% of that group. Almost 44 million people in that age bracket have received a first jab, covering 80.4% of that population.

The U.S. added at least 78,932 new cases on Friday, according to a New York Times tracker, and at least 940 people died. The U.S. has averaged 70,117 new cases a day for the past week, up 8% from the average two weeks ago.

The Biden administration will invest $1.7 billion to help states and the Centers for Disease Control and Prevention track and fight COVID-19 variants, the White House  announced Friday .

The money is from the COVID-relief law enacted last month, and includes $1 billion for expanding genomic sequencing; $400 million for studying genomic epidemiology; and $300 million for a system for sharing and analyzing sequencing data. The administration says “new and potentially dangerous strains” of the virus make up about half of COVID cases in the U.S. today.

Three top federal health officials — Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases and President Joe Biden’s chief medical officer; Dr. Rochelle Walensky, the C.D.C. director; and Dr. David Kessler, who runs the Biden administration’s vaccine effort — urged Americans to continue to make appointments and get vaccinated at a hearing on Capitol Hill on Thursday.

Kessler sought to assuage vaccine fears by reminding Americans that the vaccines that have been authorized have “an excellent safety profile.” Experts emphasize that the six clotting cases associated with the J&J vaccine are a tiny number compared with the 6.8 million people who had received the shot when the pause was announced.

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 168.50
+0.76 +0.45%
Volume: 5.32M
May 7, 2021 4:00p
P/E Ratio
29.76
Dividend Yield
2.52%
Market Cap
$443.73 billion
Rev. per Employee
$613,918
loading...
/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 53.81
+0.33 +0.62%
Volume: 4.78M
May 7, 2021 4:00p
P/E Ratio
35.35
Dividend Yield
2.55%
Market Cap
$141.94 billion
Rev. per Employee
$365,423
loading...
/zigman2/quotes/203048482/delayed
UK : U.K.: London
7,735.00 p
+55.00 +0.72%
Volume: 1.40M
May 7, 2021 4:35p
P/E Ratio
33.81
Dividend Yield
2.68%
Market Cap
£101.54 billion
Rev. per Employee
£282,763
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 39.58
+0.39 +1.00%
Volume: 33.81M
May 7, 2021 4:02p
P/E Ratio
23.15
Dividend Yield
3.94%
Market Cap
$220.78 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 183.71
+15.71 +9.35%
Volume: 4.46M
May 7, 2021 4:00p
P/E Ratio
1,753
Dividend Yield
N/A
Market Cap
$44.37 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 163.15
+2.65 +1.65%
Volume: 11.95M
May 7, 2021 4:00p
P/E Ratio
130.06
Dividend Yield
N/A
Market Cap
$65.29 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 168.50
+0.76 +0.45%
Volume: 5.32M
May 7, 2021 4:00p
P/E Ratio
29.76
Dividend Yield
2.52%
Market Cap
$443.73 billion
Rev. per Employee
$613,918
loading...
1 2
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.